PL EN


Preferences help
enabled [disable] Abstract
Number of results
2017 | 64 | 2 | 315-322
Article title

Suppression of ID1 expression in colon cancer cells increases sensitivity to 5-fluorouracil

Content
Title variants
Languages of publication
EN
Abstracts
EN
Adjuvant chemotherapy with 5-fluorouracil remains the basic treatment for patients with advanced colorectal carcinoma. The major obstacle in successful treatment is the ability of CRC cells to acquire chemoresistance. Here we examined the impact of ID1 silencing on the sensitivity of CRC cells to 5-FU. To suppress ID1 expression in HT-29 and HCT-116 cells the cells were transduced with a lentiviral vector carrying the ID1 silencing sequence. Cells with silenced ID1 showed altered expression of epithelial and mesenchymal markers and exhibited increased proliferation rate compared to the parental cells. HCT-116 cells with suppressed ID1 became sensitized to 5-FU and this was not observed in HT-29 cells. Silencing ID1 resulted in altered expression of genes encoding enzymes metabolizing 5-FU. HT-29 cells with suppressed ID1 had significantly reduced mRNA level for thymidine phosphorylase, uridine-cytydine kinase 2 and dihydropyrimidine dehydrogenase. ID1 suppression in HCT-116 cells resulted in an increase of mRNA level for thymidine phosphorylase, thymidine kinase and uridine-cytydine kinase 2 with concurrent drop of dihydropyrimidine dehydrogenase and thymidylate synthetase mRNA levels. In conclusion, ID1 expression impacts the sensitivity of colon cancer cells to 5-FU and may be considered as a potential predictive marker in CRC treatment.
Keywords
EN
colon cancer   ID1   5-fluorouracil   TYMP   TK   UCK2   DYPD   TYMS.  
Publisher

Year
Volume
64
Issue
2
Pages
315-322
Physical description
Dates
published
2017
received
2016-09-07
revised
2017-02-06
accepted
2017-02-21
(unknown)
2017-05-17
Contributors
  • Department of Molecular Medicine, Medical University of Gdansk, Gdańsk, Poland
  • Department of Molecular Medicine, Medical University of Gdansk, Gdańsk, Poland
  • Department of Molecular Medicine, Medical University of Gdansk, Gdańsk, Poland
  • Departemnt of Laboratory Medicine, Medical University of Gdansk, Gdańsk, Poland
  • Department of Molecular Medicine, Medical University of Gdansk, Gdańsk, Poland
References
  • Berridge M, Tan A, McCoy K, Wang R (1996) The biochemical and cellular basis of cell proliferation assays that use tetrazolium salts. Biochemica 4: 14-19
  • Brunner D, Frank J, Appl H, Schöffl H, Pfaller W, Gstraunthaler G (2010) Serum-free cell culture: the serum-free media interactive online database. Altex 27: 53-62.
  • Cheng YJ, Lee YC, Chiu WC, Tsai JW, Su YH, Hung AC, Chang PC, Huang CJ, Chai CY, Yuan SS (2014) High Id1 expression, a generally negative prognostic factor, paradoxically predicts a favorable prognosis for adjuvant paclitaxel plus cisplatin therapy in surgically treated lung cancer patients. Oncotarget 5: 11564-11575. doi: 10.18632/oncotarget.2595.
  • Connerney J, Andreeva V, Leshem Y, Mercado MA, Dowell K, Yang X, Lindner V, Friesel RE, Spicer DB (2008) Twist1 homodimers enhance FGF responsiveness of the cranial sutures and promote suture closure. Dev Biol 318: 323-334. doi: 10.1016/j.ydbio.2008.03.037.
  • Etienne MC, Cheradame S, Fischel JL, Formento P, Dassonville O, Renee N, Schneider M, Thyss A, Demard F, Milano G (1995) Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity. J Clin Oncol 13: 1663-1670.
  • Gajula RP, Chettiar ST, Williams RD, Nugent K, Kato Y, Wang H, Malek R, Taparra K, Cades J, Annadanam A, Yoon AR, Fertig E, Firulli BA, Mazzacurati L, Burns TF, Firulli AB, An SS, Tran PT (2015) Structure-function studies of the bHLH phosphorylation domain of TWIST1 in prostate cancer cells. Neoplasia 17: 16-31. doi: 10.1016/j.neo.2014.10.009.
  • Graham JS, Cassidy J (2012) Adjuvant therapy in colon cancer. Expert Rev Anticancer Ther 12: 99-109. doi: 10.1586/era.11.189.
  • Gumireddy K, Li A, Gimotty PA, Klein-Szanto AJ, Showe LC, Katsaros D, Coukos G, Zhang L, Huang Q (2009) KLF17 is a negative regulator of epithelial-mesenchymal transition and metastasis in breast cancer. Nat Cell Biol 11: 1297-1304. doi: 10.1038/ncb1974.
  • Hammond WA, Swaika A, Mody K (2016) Pharmacologic resistance in colorectal cancer: a review. Ther Adv Med Oncol 8: 57-84. doi: 10.1177/1758834015614530.
  • Hasselblatt M, Mertsch S, Koos B, Riesmeier B, Stegemann H, Jeibmann A, Tomm M, Schmitz N, Wrede B, Wolff JE, Zheng W, Paulus W (2009) TWIST-1 is overexpressed in neoplastic choroid plexus epithelial cells and promotes proliferation and invasion. Cancer Res 69: 2219-2223. doi: 10.1158/0008-5472.CAN-08-3176.
  • Healey MA, Deaton SL, Alder JK, Winnepenninckx V, Casero RA Jr, Herman JG (2010) Id1 overexpression is independent of repression and epigenetic silencing of tumor suppressor genes in melanoma. Epigenetics 5: 410-421.
  • Jolly MK, Boareto M, Huang B, Jia D, Lu M, Ben-Jacob E, Onuchic JN, Levine H (2015) Implications of the Hybrid Epithelial/Mesenchymal Phenotype in Metastasis. Front Oncol 5: 155. doi: 10.3389/fonc.2015.00155.
  • Kelder W, Hospers GA, Plukker JT (2006) Effects of 5-fluorouracil adjuvant treatment of colon cancer. Expert Rev Anticancer Ther 6: 785-794. doi: 10.1586/14737140.6.5.785.
  • Li B, Tsao SW, Chan KW, Ludwig DL, Novosyadlyy R, Li YY, He QY, Cheung AL (2014) Id1-induced IGF-II and its autocrine/endocrine promotion of esophageal cancer progression and chemoresistance - implications for IGF-II and IGF-IR-targeted therapy. Clin Cancer Res 20: 2651–2662. doi: 10.1158/1078-0432.CCR-13-2735.
  • Li L, Wu D (2016) miR-32 inhibits proliferation, epithelial-mesenchymal transition, and metastasis by targeting TWIST1 in non-small-cell lung cancer cells. Onco Targets Ther 9: 1489-1498. doi: 10.2147/OTT.S99931.
  • Ling F, Kang B, Sun XH (2014) Id proteins: small molecules, mighty regulators. Curr Top Dev Biol 110: 189-216. doi: 10.1016/B978-0-12-405943-6.00005-1.
  • Lombardi L, Morelli F, Cinieri S, Santini D, Silvestris N, Fazio N, Orlando L, Tonini G, Colucci G, Maiello E (2010) Adjuvant colon cancer chemotherapy: where we are and where we'll go. Cancer treatment reviews 36: S34-S41. doi: 10.1016/S0305-7372(10)70018-9.
  • Longley DB, Harkin DP, Johnston PG (2003) 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 3: 330-338. doi: 10.1038/nrc1074.
  • Maciejewska I, Sakowicz-Burkiewicz M, Pawelczyk T (2014) Id1 Expression level determines the differentiation of human dental pulp stem cells. J Dent Res 93: 576-581. doi: 10.1177/0022034514530164.
  • Offer SM, Butterfield GL, Jerde CR, Fossum CC, Wegner NJ, Diasio RB (2014) microRNAs miR-27a and miR-27b directly regulate liver dihydropyrimidine dehydrogenase expression through two conserved binding sites. Mol Cancer Ther 13: 742-751. doi: 10.1158/1535-7163.MCT-13-0878.
  • Oie S, Ono M, Fukushima H, Hosoi F, Yano H, Maruyama Y, Kojiro M, Terada T, Hirano K, Kuwano M, Yamada Y (2007) Alteration of dihydropyrimidine dehydrogenase expression by IFN-α effects the antiproliferative effects of 5-fluorouracil in human hepatocellular carcinoma cells. Mol Cancer Ther 6: 2310-2318. doi: 10.1158/1535-7163.MCT-06-0281.
  • Oyan B (2012) Why do targeted agents not work in the adjuvant setting in colon cancer? Expert Rev Anticancer Ther 12: 1337-1345. doi: 1586/era.12.111.
  • Peng JJ, Wu B, Xiao XB, Shao YS, Feng Y, Yin MX (2014) Reduced Krüppel-like factor 17 (KLF17) expression correlates with poor survival in patients with gastric cancer. Arch Med Res 45: 394-399. doi: 10.1016/j.arcmed.2014.06.005.
  • Peters GJ, Laurensse E, Leyva A, Lankelma J, Pinedo HM (1986) Sensitivity of human, murine, and rat cells to 5-fluorouracil and 5'-deoxy-5-fluorouridine in relation to drug-metabolizing enzymes. Cancer Res 46: 20-28.
  • Peters GJ, van Groeningen CJ, Laurensse EJ, Pinedo HM (1991) A comparison of 5-fluorouracil metabolism in human colorectal cancer and colon mucosa. Cancer 68: 1903-1909.
  • Qian J, Luo Y, Gu X, Zhan W, Wang X (2013) Twist1 promotes gastric cancer cell proliferation through up-regulation of FoxM1. PLoS One 8: e77625. doi: 10.1371/journal.pone.0077625.
  • Qiang L, Zhao B, Ming M, Wang N, He TC, Hwang S, Thorburn A, He YY (2014) Regulation of cell proliferation and migration by p62 through stabilization of Twist1. Proc Natl Acad Sci USA 111: 9241-9246. doi: 10.1073/pnas.1322913111.
  • Rice DP, Aberg T, Chan Y, Tang Z, Kettunen PJ, Pakarinen L, Maxson RE, Thesleff I (2000) Integration of FGF and TWIST in calvarial bone and suture development. Development 127: 1845-1855.
  • Sánchez-Tilló E, de Barrios O, Siles L, Cuatrecasas M, Castells A, Postigo A (2014) ID1 regulates U87 human cell proliferation and invasion. Clin Cancer Res 20: 2651-2662. doi: 10.3892/ol.2013.1507
  • Stankic M, Pavlovic S, Chin Y, Brogi E, Padua D, Norton L, Massagué J, Benezra R (2013) TGF-β-Id1 signaling opposes Twist1 and promotes metastatic colonization via a mesenchymal-to-epithelial transition. Cell Rep 5: 1228-1242. doi: 10.1016/j.celrep.2013.11.014.
  • Sumida T, Murase R, Onishi-Ishikawa A, McAllister SD, Hamakawa H, Desprez PY (2013) Targeting Id1 reduces proliferation and invasion in aggressive human salivary gland cancer cells. BMC Cancer 13: 141. doi: 10.1186/1471-2407-13-141.
  • Thiery JP, Acloque H, Huang RY, Nieto MA (2009) Epithelial-mesenchymal transitions in development and disease. Cell 139: 871-890. doi: 10.1016/j.cell.2009.11.007.
  • Tobin NP, Sims AH, Lundgren KL, Lehn S, Landberg G (2011) Cyclin D1, Id1 and EMT in breast cancer. BMC Cancer 11: 417. doi: 10.1186/1471-2407-11-417.
  • Yu H, Yue X, Zhao Y, Li X, Wu L, Zhang C, Liu Z, Lin K, Xu-Monette ZY, Young KH, Liu J, Shen Z, Feng Z, Hu W (2014) LIF negatively regulates tumour-suppressor p53 through Stat3/ID1/MDM2 in colorectal cancers. Nat Commun 5: 5218. doi: 0.1038/ncomms6218.
  • Zhang H, Gong J, Kong D, Liu HY (2015) Anti-proliferation effects of Twist gene silencing in gastric cancer SGC7901 cells. World J Gastroenterol 21: 2926-2936. doi: 10.3748/wjg.v21.i10.2926.
  • Zhu DJ, Chen XW, Zhang WJ, Wang JZ, Ouyang MZ, Zhong Q, Liu CC (2015) Twist1 is a potential prognostic marker for colorectal cancer and associated with chemoresistance. Am J Cancer Res 5: 2000-2011.
Document Type
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.bwnjournal-article-abpv64p315kz
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.